Prostate Cancer Grant Spotlights Columbia’s Aim to Deliver Precision Cancer Medicine
Columbia University Irving Medical Center experts in prostate cancer will lead a new team research project that tests a novel approach for personalized cancer treatment. The two-year project, funded by a $1 million Challenge Award from the Prostate Cancer Foundation, combines computational methods for targeted drug therapy, single-cell RNA sequencing and novel cancer immunotherapy. The combined approaches are behind a proof-of-concept clinical trial for patients at Bronx VA with lethal metastatic prostate cancer.
Columbia Team Awarded New Prostate Cancer Grant for Innovative Precision Cancer Research
The Prostate Cancer Foundation (PCF) has announced more than $5.5 million in research funding to six new 2018 PCF Challenge Award teams, including an interdisciplinary team at Columbia University Irving Medical Center. The Columbia team includes Systems Biology faculty Drs. Michael Shen, Andrea Califano and Cory Abate-Shen, with several leading investigators from the Herbert Irving Comprehensive Cancer Center, the James J. Peters Veterans Affairs Medical Center and Dana-Farber Cancer Institute.
Michael Shen Wins Cancer Research Innovation Award
The Bladder Cancer Advocacy Network has awarded Professor Michael Shen, PhD, the 2018 Bladder Cancer Research Innovation Award. The honor singles out scientists whose creative, novel research has great potential to advance therapies for bladder cancer, the fifth most common cancer in the U.S.
Organoids Created from Patients’ Bladder Cancers Could Guide Treatment
A study, led by Professor Michael Shen, published in Cell, details the development of patient-specific bladder cancer organioids that mimic many of the characteristics of actual tumors. The use of organoids may be useful in the future to guide treatment of patients.
Columbia Investigators Awarded New NCI Physical Sciences in Oncology Center
The Center for Topology of Cancer Evolution and Heterogeneity will combine new mathematical approaches and single-cell experimental technologies to study cellular diversity in solid tumors.